Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Resolving monocytes generated through TRAM deletion attenuate atherosclerosis
Shuo Geng, … , Ran Lu, Liwu Li
Shuo Geng, … , Ran Lu, Liwu Li
Published September 9, 2021
Citation Information: JCI Insight. 2021;6(20):e149651. https://doi.org/10.1172/jci.insight.149651.
View: Text | PDF
Research Article Inflammation

Resolving monocytes generated through TRAM deletion attenuate atherosclerosis

  • Text
  • PDF
Abstract

Polarization of low-grade inflammatory monocytes facilitates the pathogenesis of atherosclerosis. However, underlying mechanisms as well as approaches for resolving monocyte polarization conducive to the regression of atherosclerosis are not well established. In this report, we demonstrate that TRIF-related adaptor molecule (TRAM) mediated monocyte polarization in vivo and in vitro. TRAM controlled monocyte polarization through activating Src family kinase c-SRC, which not only induces STAT1/STAT5-regulated inflammatory mediators CCR2 and SIRP-α but also suppresses PPARγ-regulated resolving mediator CD200R. Enhanced PPARγ and Pex5 due to TRAM deficiency facilitated peroxisome homeostasis and reduction of cellular reactive oxygen species, further contributing to the establishment of a resolving monocyte phenotype. TRAM-deficient monocytes propagated the resolving phenotype to neighboring monocytes through CD200R-mediated intercellular communication. At the translational level, we show that TRAM-deficient mice were resistant to high-fat diet–induced pathogenesis of atherosclerosis. We further document that intravenous transfusion of TRAM-deficient resolving monocytes into atherosclerotic mice potently reduced the progression of atherosclerosis. Together, our data reveal that targeting TRAM may facilitate the effective generation of resolving monocytes conducive for the treatment of atherosclerosis.

Authors

Shuo Geng, Yao Zhang, Ziyue Yi, Ran Lu, Liwu Li

×

Figure 4

TRAM deficiency gives rise to resolving monocytes with elevated expression of CD200R both in vitro and in vivo.

Options: View larger image (or click on image) Download as PowerPoint
TRAM deficiency gives rise to resolving monocytes with elevated expressi...
(A and B) Dimensionality reduction and clustering through uniform manifold approximation and projection (UMAP) of the scRNA-Seq data from WT (A) or TRAM monocytes (B) challenged with either PBS or 100 pg/mL LPS as we described in Methods. (C) Heatmaps showing representative genes differentially expressed in different clusters of monocytes challenged with subclinical-dose LPS. (D) Dot plot comparison of representative genes differentially expressed among LPS-treated WT versus Tram−/− monocytes. (E) BM cells from WT C57 BL/6 mice and Tram−/− mice were cultured with M-CSF (10 ng/mL) for 5 days. The surface expression of CD200R was analyzed and quantified by flow cytometry. (F) Apoe−/− Tram+/+ mice and Apoe−/− Tram−/− mice were fed with HFD for 8 weeks. Surface expression of CD200R on CD11b+Ly6C++ monocytes in the peripheral blood, BM, spleen, and aorta was examined by flow cytometry. Data are representative of 2 independent experiments, and error bars represent means ± SEM. *P < 0.05, and ***P < 0.001; Student’s 2-tailed t test (n = 3 to 10 for each group).

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts